Swiss National Bank Has $2.69 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Swiss National Bank increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 28.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 78,200 shares of the company’s stock after purchasing an additional 17,200 shares during the period. Swiss National Bank’s holdings in Harmony Biosciences were worth $2,691,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Citigroup Inc. boosted its position in shares of Harmony Biosciences by 9.8% in the third quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock valued at $7,114,000 after acquiring an additional 15,859 shares during the period. HighTower Advisors LLC grew its position in Harmony Biosciences by 364.0% in the 3rd quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock worth $3,199,000 after purchasing an additional 62,729 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after purchasing an additional 93,622 shares during the period. Barclays PLC raised its position in shares of Harmony Biosciences by 110.9% during the third quarter. Barclays PLC now owns 76,862 shares of the company’s stock valued at $3,074,000 after buying an additional 40,416 shares during the last quarter. Finally, Amundi raised its position in shares of Harmony Biosciences by 243.3% during the fourth quarter. Amundi now owns 18,402 shares of the company’s stock valued at $635,000 after buying an additional 13,041 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 25,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 in the last three months. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Stock Up 0.4 %

HRMY opened at $33.35 on Friday. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 15.81, a PEG ratio of 0.47 and a beta of 0.82. The firm’s 50-day simple moving average is $36.13 and its 200-day simple moving average is $35.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million during the quarter, compared to analyst estimates of $201.25 million. During the same quarter last year, the business posted $0.45 earnings per share. The company’s revenue was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price for the company. HC Wainwright lowered their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, March 18th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.